首页 / 院系成果 / 成果详情页

Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C 会议论文

编号：

DBAC4F00CDDF38FE3C4328DC70B901BC
作者：

Wu, Junwei ;Zhou, Chenfei ;Yan, Jun ;Han, Zhengxiang ;Wang, Chun ;Qin, Zhiquan ;Jiang, Jinling ;Wang, Chunbing ;Tang, Xinyu ;Zhu, Lingjun ;Chen, Jun ;Mao, Yong ;Zhu, Liangjun ;Wei, Xiaowei ;Shangguan, Chengfang ;Zhang, Jun
语种：

英文
会议名称：

JOURNAL OF CLINICAL ONCOLOGY
会议地点：

ELECTR NETWORK
收录：
推荐引用方式
GB/T 7714：

Wu Junwei,Zhou Chenfei,Yan Jun, et al. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C [J].JOURNAL OF CLINICAL ONCOLOGY,2024,42(16).
APA：

Wu Junwei,Zhou Chenfei,Yan Jun,Han Zhengxiang,&Zhang Jun.(2024).Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C .JOURNAL OF CLINICAL ONCOLOGY,42(16).
MLA：

Wu Junwei, et al. "Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C" .JOURNAL OF CLINICAL ONCOLOGY 42,16(2024).
入库时间：

8/14/2026 5:41:31 PM
更新时间：

8/14/2026 5:42:01 PM

浏览次数：2  下载次数：0

浏览次数：2

下载次数：0

打印次数：0